Sánchez VLD

Language: Spanish
References: 17
Page: 159-166
PDF size: 232.74 Kb.

ABSTRACT

Background: Medical Intensive Care costs of main pathologies treated in Mexico are unknown.
Objectives: To define the medical intensive care costs of main pathologies in Mexico since the providers’ perspective.
Patient and methods: Design: Prospective, multicenter cost analysis study. Sites: 6 Mexican ICU’s Mexican Institute of Social Security. Period: 1 year. Patients: 16 years or older. Variables: Demographic, clinical, APACHE II, Brussels score and NEMS. Pharmacoeconomic method: Cost analysis cost from the providers’ perspective with bottom-up approach. Sponsorship: CONACyT. Statistical analysis: descriptive statistics.
Results: 2,463 patients were enrolled, 50.2% women. Mean age was 53.7 ± 18.5 years. ICU and hospital length of stay were 6.4 ± 5.0 days and 19.1 ± 16.7 days, respectively. Main diagnoses were sepsis 449 (18.2%), coronary artery disease 432 (17.5%) and diabetic ketoacidosis 151 (6.1%). Total costs in the ICU per patient were 203,303 ± 199,192, 123,430 ± 164,497 and 149,253 ± 143,503, respectively.
Conclusions: Sepsis is the most expensive pathology, followed by diabetic ketoacidosis. The most expensive items were day-bed, drugs, surgery and dialysis.

REFERENCES

1. Cerra FB, Champion H, Chulay M, et al. Critical Care in the United States: coordinating intensive care resources for positive and cost-efficient patient outcomes. Anaheim, CA, USA: Society of Critical Care Medicine;1992.

2. Chalfin DB. Analysis of cost-effectiveness in intensive care: An overview of methods and a review of applications to problems in critical care medicine. Curr Opin Anaesthesiol 1996;9:129-133.

3. Spivack D. The high cost of acute health care: A review of escalating costs and limitations of such exposure in intensive care units. Am Rev Respir Dis 1987;136:1007-1011.

4. Fair allocation of intensive care unit resources (ATS Board of Directors Position Statement). Am J Respir Crit Care Med 1997;156:1282-1301.

5. Milbrandt EB, Kersten A, Rahim MT, Dremsizov TT, Clermont G, Cooper LM, et al. Growth of intensive care unit resource use and its estimated cost in medicare. Crit Care Med 2008;36:2504-10.

6. Secretaría de Salud. Módulo de estimación de costos hospitalarios. México, 2004.

7. Walley T, Davey P. Pharmacoeconomics: A challenge for clinical pharmacologists. Br J Clin Pharmacol 1995;40:199-202.

8. Walley T, Haycox A. Pharmacoeconomics: Basic concepts and terminology. Br J Clin Pharmacol 1997;43:343-8.

9. Schulman K, Linas BP. Pharmacoeconomics: State of the art in 1997. Annu Rev Public Health 1997;18:529-48.

10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification. Crit Care Med 1985;13:818-829.

11. Bernard GR, Doig G, Hudson LD, Lemeshow S, Marshall JC, Russell J, et al. Quantification of organ failure for clinical trials and clinical practice. Am J Respir Crit Care Med 1995;151:A323.

12. Miranda DR, Moreno R, Iapichino G. Nine Equivalents of Nursing Manpower Use Score (NEMS). Intensive Care Med 1997;23:760-765.

13. http://www.banxico.org.mx/polmoneinflacion/servicios/calcDeInflacion/calcDeInflac.html Consultada el 15 de marzo del 2010.

14. López MJ, Martín SJI, Del Llano JA, Pascual PR, Treceño CJ. Evaluación de costes en cuidados intensivos. A la búsqueda de una unidad relativa de valor. Med Intensiva 2003;27:453-62.

15. Csomós A, Jancskó M, Edbrooke D. Comparative costing analysis of intensive care services between Hungary and United Kingdom. Intensive Care Med 2005;31:1280-3.

16. Flaatten H, Kvale R. Cost of intensive care in a Norwegian university hospital 1997-1999. Crit Care 2003;7:72-8.

17. Sogayar AMC, Machado FR, Rea-Neto A, Dornas A, Grion CMC, Lobo SMA, et al. A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics 2008;26:425-34.